Baxter Q1 2024: sales $3.59B (+3% CC), adj. EPS $0.65, beating guidance; FY2024 adj. EPS guidance $2.88-$2.98

BAXTER INTERNATIONAL INC

2024-Q1 EPS reported $0.07 revenue$3,592,000,000

Q1 sales $3.59B (+2% reported, +3% CC); GAAP EPS $0.07; adj. EPS $0.65, above guidance.
FY 2024 guidance: sales growth ~2% reported, 2-3% CC; adj. EPS $2.88-$2.98.
FDA clearance for Novum IQ large volume infusion pump and Dose IQ Safety Software.
CEO cited solid operational execution and benefits from new operating model.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BAXTER INTERNATIONAL INC updated its first quarter 2024 guidance (raised).

Period: first quarter 2024
Guidance: raised
Result: reported results

Exact text from the filing

On May 2, 2024, Baxter International Inc. (the Company) issued an earnings press release for the period ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BAXTER INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001628280-24-019783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.